SCHEMBL143878

SCHEMBL143878

COC(=O)C1=C(c2ccccc2)c2c(OC)cccc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 1.00
FGFR2 P21802 6/20 1.00
FGFR4 P22455 6/20 1.00
FGFR3 P22607 6/20 1.00
SRC P12931 3/20 1.00
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
FABP3 P05413 1/20 0.47
FABP4 P15090 1/20 0.47
FABP5 Q01469 1/20 0.47
EGFR P00533 1/20 0.47
PIM1 P11309 1/20 0.47
HSP90AA1 P07900 2/20 0.46
HSP90AB1 P08238 1/20 0.46
PPARG P37231 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
MAPT P10636 6/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17969780 0.81 FGFR1 (0.88) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL143675 0.81 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL11720920 0.77 FGFR1 (0.75) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL145725 0.77 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL3904565 0.76 FGFR1 (0.61) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL31019062 0.73 FGFR1 (0.57) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL18850691 0.73 FGFR1 (0.63) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL7174236 0.72 FABP4 (0.62) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL3886882 0.72 FGFR1 (0.56) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL144476 0.71 FGFR1 (0.74) FGFR1FGFR2FGFR4FGFR3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.